T01 study section is a recurring Special Emphasis Panel that reviews applications on Carrer Development Awards (K Mechanism). The topics covered by this study section include applications on career development that study injury and disorders of brain and nervous system. Studies may be mechanistic, preclinical, translational or clinical with focus on the underlying cause of above disorders. Studies may also be focused on development of potential therapeutics, biomarker or assays relevant to above conditions.

Topics


  • Preclinical, clinical and translational aspects on brain and neuronal injury (including but not limited to TBI, spinal cord injury, epilepsy), neurovascular disorders (including but not limited to stroke and ischemia) using animal models, organoids, organ-on-chip as well as human subjects and specimens.
  • Therapeutic strategies to enhance recovery of function following injury of brain and nervous system.
  • Studies on neuroplasticity, neuroprotection and circuit disorder related to brain diseases and disorders.
  • Neuroimmunology and neuroinflammation of CNS and PNS.
  • Preclinical and clinical studies on autoimmune disorders of the nervous system.
  • Studies on Primary and secondary brain tumors (including but not limited to glioma/glioblastoma/medulloblastoma) in context of neuroimmunology, neuroinflammation and/or neuro-modulatory effect of the CNS.
  • Application involving neuroimaging, electrophysiological recording and stimulation, deep brain stimulation or computational modeling in brain, neuronal injury and neuronal disorders.
  • Cellular/molecular approaches, including genetic or epigenetic methods in understanding mechanistic aspects brain, neuronal injury and neuronal disorders and recovery from them.
  • Applications using animal models and organoids for studying above disorders and diseases with a focus on clinical outcome.
  • Applications on neurobiology of pain and itch; pain mediation, therapy related to pain management, mechanisms of action of analgesics

 

Last updated: 02/23/2026 14:58